Ginkgo Bioworks $DNA released their 2023 results, and it's not pretty. Downstream revenues are drying up, and milestone pool opportunities aren't providing as many growth opportunities as investors had hoped. Cell engineering revenues disappointed with only $144 million in 2023 versus the expected $175 million flat revenue growth yearoveryear. Will Ginkgo be able to turn this ship around? Or is the synthetic biology company just another wonderful story?

RESEARCH PIECES USED IN THIS VIDEO:
1. Can Ginkgo Bioworks Scale Fast Enough Before It Fails?
https://www.nanalyze.com/2023/09/can...
2. Ginkgo Bioworks Stock Not Looking Good
   • Ginkgo Bioworks Stock | Not Looking Good  
3. Ginkgo Bioworks: Beware of the Bait and Switch
https://www.nanalyze.com/2023/03/gink...
4. Ginkgo Bioworks Responds to Short Seller Report
https://www.nanalyze.com/2021/11/gink...

CHAPTERS:
00:00 Intro
01:59 Key points in 2023
03:16 Types of revenues
06:45 Expectations vs. reality
08:18 Cell engineering revenue
08:57 Ginkgo's history
10:22 A shift in focus
11:25 Parting thoughts

ABOUT US:
This video is brought to you by Nanalyze, a boutique media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #investments in a language that is futureproof and easy to understand.

Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30day trial of our monthly subscription with no strings attached: https://www.nanalyze.com/becomeanan...

DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our YouTube videos or on our website, whether for the purpose of making an investment or otherwise.

#Ginkgo
#GinkgoBioworks
$DNA